Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disease affecting an increasing percentage of general population worldwide. Patients with T2DM are frequently characterized by impaired renal function, primarily as a result of diabetic kidney injury, but also by other contributing factors, such as hypertension, atherosclerosis, and medications. Sodium-glucose cotransporter (SGLT)-2 inhibitors have emerged as a new, promising class of antidiabetic agents with actions that seem to extend beyond their hypoglycemic effect.

Drugs and the Kidneys: Clinical Pharmacology Perspectives

“…The renal effects of SGLT‐2 inhibitors and other antidiabetic drugs are the focus of the review by Lioudaki et al . SGLT‐2 is a low‐affinity, high‐capacity, Na + /glucose cotransporter expressed on the luminal surfaces of proximal tubular cells.…”

SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control

“…Sodium-glucose cotransporter (SGLT) 2 inhibitors also called glucoretics or gliflozins are members of a relatively new group of antidiabetic agents with promising cardioprotective and renoprotective effects beyond their glucose lowering efficacies. [1][2][3] Kidneys are involved in glucose homeostasis via gluconeogenesis and glucose reabsorption. Under normoglycemic conditions kidneys of healthy individuals filter about 140-160 grams of glucose daily.…”